Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Centanafadine: First Approval

Drugs. 2026 Oct 24. doi: 10.1007/s40265-026-02411-0. Online ahead of print.ABSTRACTCentanafadine (SIMTRIYO®) is a first-in-class, sustained-release norepinephrine, dopamine and serotonin reuptake inhibitor and central nervous system...

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan

Lancet. 2026 Oct 24:S0140-6736(26)01782-4. doi: 10.1016/S0140-6736(26)01782-4. Online ahead of print.ABSTRACTBACKGROUND: Trifluridine-tipiracil (FTD-TPI) plus bevacizumab is the standard treatment for refractory metastatic colorectal cancer. However, the...
close chatgpt icon
ChatGPT

Enter your request.

← CME/CPD